98 related articles for article (PubMed ID: 23876834)
21. [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].
Warth A
Pathologe; 2015 Nov; 36 Suppl 2():194-200. PubMed ID: 26391251
[TBL] [Abstract][Full Text] [Related]
22. Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases.
Pfarr N; Penzel R; Klauschen F; Heim D; Brandt R; Kazdal D; Jesinghaus M; Herpel E; Schirmacher P; Warth A; Weichert W; Endris V; Stenzinger A
Genes Chromosomes Cancer; 2016 Nov; 55(11):821-33. PubMed ID: 27218826
[TBL] [Abstract][Full Text] [Related]
23. Large personalised medicine trial in lung cancer heralds new research partnership.
Torjesen I
BMJ; 2014 Apr; 348():g2837. PubMed ID: 24742663
[No Abstract] [Full Text] [Related]
24. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis.
Parker JL; Kuzulugil SS; Pereverzev K; Mac S; Lopes G; Shah Z; Weerasinghe A; Rubinger D; Falconi A; Bener A; Caglayan B; Tangri R; Mitsakakis N
Cancer Med; 2021 Mar; 10(6):1955-1963. PubMed ID: 33620160
[TBL] [Abstract][Full Text] [Related]
25. Personalized therapy on the horizon for squamous cell carcinoma of the lung.
Kim HS; Mitsudomi T; Soo RA; Cho BC
Lung Cancer; 2013 Jun; 80(3):249-55. PubMed ID: 23489560
[TBL] [Abstract][Full Text] [Related]
26. Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
Kim L; Tsao MS
Eur Respir J; 2014 Oct; 44(4):1011-22. PubMed ID: 25102961
[TBL] [Abstract][Full Text] [Related]
27. Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.
Nixon NA; Khan OF; Imam H; Tang PA; Monzon J; Li H; Sun G; Ezeife D; Parimi S; Dowden S; Tam VC
Cancer; 2017 Dec; 123(23):4672-4679. PubMed ID: 28817175
[TBL] [Abstract][Full Text] [Related]
28. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
König K; Peifer M; Fassunke J; Ihle MA; Künstlinger H; Heydt C; Stamm K; Ueckeroth F; Vollbrecht C; Bos M; Gardizi M; Scheffler M; Nogova L; Leenders F; Albus K; Meder L; Becker K; Florin A; Rommerscheidt-Fuss U; Altmüller J; Kloth M; Nürnberg P; Henkel T; Bikár SE; Sos ML; Geese WJ; Strauss L; Ko YD; Gerigk U; Odenthal M; Zander T; Wolf J; Merkelbach-Bruse S; Buettner R; Heukamp LC
J Thorac Oncol; 2015 Jul; 10(7):1049-57. PubMed ID: 26102443
[TBL] [Abstract][Full Text] [Related]
29. Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer.
Dequeker EM; Keppens C; Egele C; Delen S; Lamy A; Lemoine A; Sabourin JC; Andrieu C; Ligtenberg M; Fetique D; Tops B; Descarpentries C; Blons H; Denoux Y; Aube C; Penault-Llorca F; Hofman P; Leroy K; Le Marechal C; Doucet L; Duranton-Tanneur V; Pedeutour F; Soubeyran I; Côté JF; Emile JF; Vignaud JM; Monhoven N; Haddad V; Laurent-Puig P; van Krieken H; Nowak F; Lonchamp E; Bellocq JP; Rouleau E
J Mol Diagn; 2016 Mar; 18(2):205-14. PubMed ID: 26752307
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement.
Slavik T; Asselah F; Fakhruddin N; El Khodary A; Torjman F; Anis E; Quinn M; Khankan A; Kerr KM
Clin Lung Cancer; 2014 Nov; 15(6):398-404. PubMed ID: 25043210
[TBL] [Abstract][Full Text] [Related]
31. The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.
Vrancken A; Lepers S; Peeters L; Oyen C; Dooms C; Nackaerts K; Verbeken E; Wauters I; Weynand B; Vansteenkiste J
Lung Cancer; 2016 Dec; 102():96-100. PubMed ID: 27987596
[TBL] [Abstract][Full Text] [Related]
32. Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.
van de Ven M; Koffijberg H; Retèl V; Monkhorst K; Smit E; van Harten W; IJzerman M
J Mol Diagn; 2021 Apr; 23(4):484-494. PubMed ID: 33493663
[TBL] [Abstract][Full Text] [Related]
33. Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys.
Keppens C; Schuuring E; Dequeker EMC
Virchows Arch; 2021 May; 478(5):995-1006. PubMed ID: 33225398
[TBL] [Abstract][Full Text] [Related]
34. [Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations].
Hofman V; Ilie M; Long E; Lassalle S; Butori C; Bence C; Washetine K; Lalvee S; Hofman P
Bull Cancer; 2014 Oct; 101(10):958-65. PubMed ID: 25373695
[TBL] [Abstract][Full Text] [Related]
35. Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology.
Buil-Bruna N; Sahota T; López-Picazo JM; Moreno-Jiménez M; Martín-Algarra S; Ribba B; Trocóniz IF
Cancer Res; 2015 Jun; 75(12):2416-25. PubMed ID: 25939602
[TBL] [Abstract][Full Text] [Related]
36. [Regional molecular genetics centers in thoracic oncology: what and who should be tested?].
Barlesi F; Tomasini P; Fina F; Secq V; Greillier L; Nanni-Metellus I; Garcia S; Ouafik L
Bull Cancer; 2013; 100(7-8):737-41. PubMed ID: 23823903
[TBL] [Abstract][Full Text] [Related]
37. Defining actionable mutations for oncology therapeutic development.
Carr TH; McEwen R; Dougherty B; Johnson JH; Dry JR; Lai Z; Ghazoui Z; Laing NM; Hodgson DR; Cruzalegui F; Hollingsworth SJ; Barrett JC
Nat Rev Cancer; 2016 Apr; 16(5):319-29. PubMed ID: 27112209
[TBL] [Abstract][Full Text] [Related]
38. Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues.
Berghoff AS; Bartsch R; Wöhrer A; Streubel B; Birner P; Kros JM; Brastianos PK; von Deimling A; Preusser M
Acta Neuropathol; 2014 Dec; 128(6):879-91. PubMed ID: 25287912
[TBL] [Abstract][Full Text] [Related]
39. Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients.
Mizuno T; Yoshida T; Sunami K; Koyama T; Okita N; Kubo T; Sudo K; Shimoi T; Ueno H; Saito E; Katanoda K; Shibata T; Yonemori K; Okusaka T; Boku N; Ohe Y; Hiroshima Y; Ueno M; Kuboki Y; Doi T; Nakamura K; Kohno T; Yatabe Y; Yamamoto N
Jpn J Clin Oncol; 2021 Dec; 51(12):1757-1760. PubMed ID: 34622931
[TBL] [Abstract][Full Text] [Related]
40. [Molecular diagnostics of non-small cell lung cancer: New markers and technologies].
Warth A; Endris V; Kriegsmann M; Stenzinger A; Penzel R; Pfarr N; Weichert W
Pathologe; 2015 Mar; 36(2):154-63. PubMed ID: 25820445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
